FI972922A - Tarkkaamattomuuden ja yliaktiivisuuden hoito - Google Patents

Tarkkaamattomuuden ja yliaktiivisuuden hoito Download PDF

Info

Publication number
FI972922A
FI972922A FI972922A FI972922A FI972922A FI 972922 A FI972922 A FI 972922A FI 972922 A FI972922 A FI 972922A FI 972922 A FI972922 A FI 972922A FI 972922 A FI972922 A FI 972922A
Authority
FI
Finland
Prior art keywords
hyperactivity
inattention
treatment
tomoxetine
deficit
Prior art date
Application number
FI972922A
Other languages
English (en)
Swedish (sv)
Other versions
FI119354B (fi
FI972922A0 (fi
Inventor
John H Heiligenstein
Gary D Tollefson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23463572&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI972922(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of FI972922A publication Critical patent/FI972922A/fi
Publication of FI972922A0 publication Critical patent/FI972922A0/fi
Application granted granted Critical
Publication of FI119354B publication Critical patent/FI119354B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Plural Heterocyclic Compounds (AREA)
FI972922A 1995-01-11 1997-07-09 Tomoksetiinin käyttö tarkkaavaisuus- ja yliaktiivisuushäiriön (ADHD) hoitoon FI119354B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37134195 1995-01-11
US08/371,341 US5658590A (en) 1995-01-11 1995-01-11 Treatment of attention-deficit/hyperactivity disorder
PCT/US1996/000091 WO1996021430A1 (en) 1995-01-11 1996-01-04 Treatment of attention-deficit/hyperactivity disorder
US9600091 1996-01-04

Publications (3)

Publication Number Publication Date
FI972922A true FI972922A (fi) 1997-07-09
FI972922A0 FI972922A0 (fi) 1997-07-09
FI119354B FI119354B (fi) 2008-10-31

Family

ID=23463572

Family Applications (1)

Application Number Title Priority Date Filing Date
FI972922A FI119354B (fi) 1995-01-11 1997-07-09 Tomoksetiinin käyttö tarkkaavaisuus- ja yliaktiivisuushäiriön (ADHD) hoitoon

Country Status (28)

Country Link
US (1) US5658590A (fi)
EP (1) EP0721777B1 (fi)
JP (2) JPH10512262A (fi)
KR (1) KR19980701276A (fi)
CN (2) CN1168095A (fi)
AT (1) ATE222757T1 (fi)
AU (1) AU688665B2 (fi)
BR (1) BR9606903A (fi)
CA (1) CA2209735C (fi)
CZ (1) CZ292226B6 (fi)
DE (2) DE122005000011I2 (fi)
DK (1) DK0721777T3 (fi)
ES (1) ES2181845T3 (fi)
FI (1) FI119354B (fi)
FR (1) FR10C0041I2 (fi)
HU (1) HU227306B1 (fi)
LU (1) LU91238I2 (fi)
NL (1) NL300180I2 (fi)
NO (1) NO317027B1 (fi)
NZ (1) NZ301500A (fi)
PL (1) PL187573B1 (fi)
PT (1) PT721777E (fi)
RO (1) RO118374B1 (fi)
RU (1) RU2163802C2 (fi)
SI (1) SI0721777T1 (fi)
TR (1) TR199700627T1 (fi)
UA (1) UA43385C2 (fi)
WO (1) WO1996021430A1 (fi)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
GB9613243D0 (en) * 1996-06-25 1996-08-28 Britannia Pharmaceuticals Ltd Attention deficit hyperactive disorder
AU9214498A (en) * 1997-09-23 1999-04-12 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
UA56257C2 (uk) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
US5902797A (en) * 1997-11-10 1999-05-11 Beth Israel Deaconess Medical Center Nutritional supplement for use in the treatment of attention deficit
CN1301164A (zh) * 1998-04-09 2001-06-27 法玛西雅厄普约翰美国公司 神经病症的新疗法
US6586427B2 (en) 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
ES2351149T3 (es) * 1998-11-09 2011-02-01 Biogen Idec Inc. Anticuerpo quimérico dirigido contra cd20, el rituxan, para uso en el tratamiento de la leucemia linfocítica crónica.
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6898455B2 (en) * 1999-10-29 2005-05-24 The Mclean Hospital Corporation Method for providing optimal drug dosage
US6400978B1 (en) 1999-10-29 2002-06-04 The Mclean Hospital Corporation Method and apparatus for detecting mental disorders
BR0108980A (pt) * 2000-03-07 2003-06-03 Lilly Co Eli Aplicação e formulação farmacêuticas compreendendo inibidor de reabsorção de norepinefrina
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US20040034106A1 (en) * 2001-11-06 2004-02-19 Read Holly Ann Treatment of anxiety disorders
WO2003049724A1 (en) * 2001-12-11 2003-06-19 Eli Lilly And Company Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
WO2004017977A2 (en) 2002-08-23 2004-03-04 Eli Lilly And Company 2- (phenoxymethyl)- and 2- (phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
GB0219687D0 (en) 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
WO2004103356A2 (en) * 2003-05-15 2004-12-02 Eli Lilly And Company Treatment of emotional dysregulation
WO2005011583A2 (en) * 2003-07-28 2005-02-10 Leslie Joe Dunaway Treatment of allergic rhinitis and asthma
CA2536161A1 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
EP1660064A2 (en) * 2003-08-27 2006-05-31 Eli Lilly And Company Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
WO2005065673A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Atomoxetine formulations
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
WO2005115396A2 (en) * 2004-05-27 2005-12-08 Warner-Lambert Company Llc Combination of atomoxetine and a 5t1a receptor agonist for treating adhd and other disorders
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
CA2561387A1 (en) * 2004-06-28 2006-01-12 Teva Pharmaceutical Fine Chemicals S.R.L. An isolated atomoxetine impurity, processes for the preparation of atomoxetine impurities and their use as reference standards
EP1768949A2 (en) * 2004-07-22 2007-04-04 Teva Pharmaceutical Fine Chemicals S.R.L. Polymorphs of atomoxetiene hydrochloride
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
EP2417969A1 (en) 2004-10-21 2012-02-15 Aptalis Pharmatech, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US7569729B2 (en) * 2005-04-05 2009-08-04 Teva Pharmaceutical Fine Chemicals S.R.L. Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
AU2006318476A1 (en) * 2005-11-23 2007-05-31 Auspex Pharmaceuticals, Inc. Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity
JP2009518337A (ja) 2005-12-07 2009-05-07 エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ 皮質カテコールアミン作動性神経伝達のモジュレーターとしての二置換フェニルピペリジン
US20080020387A1 (en) * 2006-03-31 2008-01-24 Lawrence Donald G Biomarker-optimized adhd treatment
US20080146675A1 (en) * 2006-04-05 2008-06-19 Eugenio Castelli Stable Atomoxetine Hydrochloride, a process for the preparation thereof, and an analytical control of its stability
US20080031932A1 (en) * 2006-08-04 2008-02-07 Watson Laboratories, Inc. Transdermal atomoxetine formulations and associated methods
US20080145318A1 (en) * 2006-12-13 2008-06-19 Midha Kamal K Atomoxetine formulations and associated methods
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
US20100069390A1 (en) * 2008-09-05 2010-03-18 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit/hyperactivity disorder (ADHD)
RU2395313C2 (ru) * 2008-10-15 2010-07-27 Татьяна Прохоровна Тетерина Способ коррекции синдрома дефицита внимания и гиперактивности
CA2782285A1 (en) 2009-12-02 2011-06-09 Luigi Mapelli Fexofenadine microcapsules and compositions containing them
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
SG193587A1 (en) 2011-03-23 2013-10-30 Ironshore Pharmaceuticals & Dev Inc Methods and compositions for treatment of attention deficit disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
AU2013217013B2 (en) 2012-02-08 2017-04-20 Supernus Pharmaceuticals, Inc. Modified release formulations of viloxazine
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
PT2838510T (pt) 2013-11-08 2016-11-23 Lilly Co Eli Solução de atomoxetina
CA2936741C (en) 2014-10-31 2018-11-06 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457121A (en) * 1994-09-02 1995-10-10 Eli Lilly And Company Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake
ZA958725B (en) * 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine

Also Published As

Publication number Publication date
DK0721777T3 (da) 2002-10-07
CA2209735A1 (en) 1996-07-18
AU688665B2 (en) 1998-03-12
EP0721777A3 (en) 1997-03-05
US5658590A (en) 1997-08-19
ATE222757T1 (de) 2002-09-15
NZ301500A (en) 2000-07-28
CZ292226B6 (cs) 2003-08-13
UA43385C2 (uk) 2001-12-17
WO1996021430A1 (en) 1996-07-18
JP2005325139A (ja) 2005-11-24
FR10C0041I2 (fi) 2011-04-29
FR10C0041I1 (fi) 2010-10-15
HU227306B1 (en) 2011-03-28
DE69623141D1 (de) 2002-10-02
FI119354B (fi) 2008-10-31
RU2163802C2 (ru) 2001-03-10
NL300180I2 (nl) 2005-08-01
FI972922A0 (fi) 1997-07-09
HUP9801283A3 (en) 1999-09-28
CZ214597A3 (cs) 1998-01-14
BR9606903A (pt) 1997-10-21
LU91238I2 (fr) 2006-07-03
DE122005000011I2 (de) 2006-02-09
NO973170D0 (no) 1997-07-08
AU4693896A (en) 1996-07-31
NO973170L (no) 1997-09-02
HUP9801283A2 (hu) 1999-06-28
DE69623141T2 (de) 2003-04-24
ES2181845T3 (es) 2003-03-01
JPH10512262A (ja) 1998-11-24
NL300180I1 (nl) 2005-05-02
EP0721777A2 (en) 1996-07-17
PL321273A1 (en) 1997-11-24
RO118374B1 (ro) 2003-05-30
CN1781480A (zh) 2006-06-07
EP0721777B1 (en) 2002-08-28
CN1168095A (zh) 1997-12-17
CA2209735C (en) 2002-10-01
TR199700627T1 (xx) 1998-01-21
SI0721777T1 (en) 2003-02-28
NO317027B1 (no) 2004-07-26
PL187573B1 (pl) 2004-08-31
PT721777E (pt) 2002-11-29
KR19980701276A (ko) 1998-05-15
MX9705117A (es) 1997-10-31
DE122005000011I1 (de) 2005-06-23

Similar Documents

Publication Publication Date Title
FI972922A (fi) Tarkkaamattomuuden ja yliaktiivisuuden hoito
EP0909561A3 (en) Use of reboxetine for the treatment of attention-deficit/hyperactivity disorder
BR9203502A (pt) Curativo e processo para sua producao
ES2172587T3 (es) Composicion que comprende morfina, polipirrolidona y poli-oxido de alquileno.
CY1113355T1 (el) Χρηση θεραπειας νευροτοξινης για θεραπευτικη αγωγη ουρολογικων και σχετικων διαταραχων
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
EA199700170A1 (ru) Способ получения некоторых азациклогексапетидов
PT946166E (pt) Utilizacao de inibidores das metaloproteinases da matriz para tratar disturbios neurologicos e promover a cicatrizacao de feridas
DE60212613D1 (de) Doxycyclin zur behandlung von akne
MX9800589A (es) Tratamiento de desorden de la falta de atencion/hiperactividad.
BR9707674A (pt) Uso de inibidores de anidrase carbÈnico para tratamento de edema macular.
DE3162611D1 (de) Method of gas-chromizing steels
PT829262E (pt) Utilizacao de inibidores de pkc para o fabrico de um medicamento para o tratamento de disfuncoes sexuais.
ES2109678T3 (es) Tratamiento de tejido de lana y de mezcla de lana.
ATE161814T1 (de) Mittel zur behandlung von bioabfällen
ATE184487T1 (de) Transdermales therapeutisches system für silatranverbindungen
NO942917L (no) Arylalkoksyfenoksy-imidazolinforbindelser
PT1304107E (pt) Utilizacao de derivados de oxazolidininas para o tratamento da psoriase
RU94003555A (ru) Способ лечения алопеции
GEU1998397Y (en) Method for Primary Prestationary Treatment of the Wound

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 119354

Country of ref document: FI

SPCF Supplementary protection certificate application filed

Free format text: SPC C20090009

Spc suppl protection certif: C20090009

SPCG Supplementary protection certificate granted

Spc suppl protection certif: 351

Extension date: 20190527

MA Patent expired